Viking Therapeutics Soars on Positive NASH Trial Results
Viking Therapeutics' liver disease treatment for nonalcoholic steatohepatitis (NASH) led to a significant reduction in liver fat and other lipid abnormalities in patients over 12 weeks compared to a placebo. The market for NASH treatments is expected to reach $24.3 billion by 2028. Viking's stock initially yo-yoed but hit a record high after the promising test results were unveiled, with shares trading near a record high and remaining well above their 50-day and 200-day moving averages.